- Trial phase
- Approved
- Time to market
- Already approved and commercialized (first FDA approval June 2017 for ABSSSI; second indication October 2019 for CABP)
- Why 4/10
- BAXDELA is an already-approved, commercial-stage product with no pending regulatory decision or pivotal readout. It is one of several products in CorMedix's diversified portfolio (acquired via Melinta). The next hard, dated catalyst for CorMedix overall is the REZZAYO sNDA PDUFA (priority review, Q1 2027), not BAXDELA. Per the impact score rubric, an approved drug with no pending binary catalyst scores 3-5; BAXDELA's contribution to the company is moderate, so a 4 is appropriate.
BAXDELA is a mature, already-approved product with no upcoming binary catalyst. The next meaningful catalyst for CorMedix is the REZZAYO sNDA PDUFA (priority review, expected Q1 2027) for prophylaxis of invasive fungal disease, and the closing of the Heron Therapeutics asset acquisition (expected Q1 2027). BAXDELA's contribution to CorMedix's revenue is not separately disclosed but is part of the Melinta portfolio; investors should watch the Q4 2026 earnings for any product-level revenue breakdown.
Price Chart
Executive Summary
BAXDELA (delafloxacin) is an FDA-approved fluoroquinolone antibiotic for acute bacterial skin and skin structure infections (ABSSSI, approved June 2017) and community-acquired bacterial pneumonia (CABP, approved October 2019). It was originally developed by Melinta Therapeutics, which CorMedix (CRMD) acquired for $300M in September 2025. BAXDELA is one of seven marketed products in CorMedix's portfolio, but it is not the company's lead revenue driver (DefenCath is). As an already-approved, commercial-stage drug with no pending regulatory catalysts, BAXDELA contributes to CorMedix's diversified revenue base but does not represent a binary event for the stock.
How It Works
BAXDELA (delafloxacin) is a fluoroquinolone antibiotic that kills bacteria by interfering with two bacterial enzymes (DNA gyrase and topoisomerase IV) that bacteria need to replicate their DNA. It is available in both intravenous (IV) and oral tablet forms, allowing patients to start treatment in the hospital and transition to pills at home. It is effective against a broad range of Gram-positive, Gram-negative, and atypical bacteria that cause skin infections and pneumonia.
Trial Status
BAXDELA is fully approved by the FDA for two indications: acute bacterial skin and skin structure infections (ABSSSI, approved June 2017) and community-acquired bacterial pneumonia (CABP, approved October 2019). It is commercially available in both IV and oral formulations. No further pivotal trials are underway for BAXDELA.
The Two-Sided Case
Upcoming Catalysts
- REZZAYO (rezafungin) sNDA for prophylaxis of invasive fungal disease: FDA accepted with Priority Review, PDUFA expected in Q1 2027.
- Closing of Heron Therapeutics asset acquisition (expected Q1 2027), adding four commercial products (ZYNRELEF, APONVIE, CINVANTI, SUSTOL) with ~$125M-$150M in pro forma 2027 revenue.
- Q4 2026 earnings (expected early 2027) for full-year revenue and product-level performance.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CorMedix Inc. DEFA14A CRMD ·Originating report